Stay updated on ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial

Sign up to get notified when there's something new on the ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:51:34.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the efficacy or safety comparison between ABT-165 plus FOLFIRI and bevacizumab plus FOLFIRI in participants with previously treated metastatic colorectal cancer.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:38.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying the diagnosis and health conditions required for inclusion in the study. Previously, this section had no information provided.
    Difference
    12%
    Check dated 2024-05-22T20:33:26.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    1.0%
    Check dated 2024-04-30T22:49:32.000Z thumbnail image

Stay in the know with updates to ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ABT-165 Combo vs Bevacizumab Combo in Metastatic CRC Clinical Trial page.